Michael Higgins on Biotech Names with Major Market Potential (ANX, CYTR,...
By George S. Mack A bit of luck and a lot of capital: Drug companies need both to navigate the seemingly perpetual path leading to the market debut of a new drug. Brinson Patrick Securities Managing...
View ArticleNeoStem Inc. (NYSEMKT:NBS): On the Leading Edge of the Advancement of Cell...
By Craig Keolanui Is stem cell therapy going to be to the biotechnology industry what Tesla Motors is to the automotive industry? Stem cell therapy has waited at the sidelines while investors pump...
View Article
More Pages to Explore .....
